ABSTRACT
The advances in pharmaceutical inhalation aerosol technology occurring since the turn of the millennium have increased the potential of pulmonary drug delivery substantially. In parallel with the new products, the breadth of application has increased to include the treatment of chronic obstructive pulmonary disease, a range of infectious diseases, diabetes, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension. Pre-clinical studies and clinical trials covering yet a range of other potential applications of orally inhaled products include the use of a broader range of biologics and also nanomaterials that may help further advance the pulmonary drug delivery market. Successful aerosol therapy has given research and development a boost, and the prospects of even greater opportunities for disease management is emerging from patient compliance, adherence tools, and new classes of drugs for local and systemic delivery through the lungs.
